RhumbLine Advisers
BBNX

RhumbLine Advisers’s Beta Bionics BBNX Stock Holding History

RhumbLine Advisers’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$465K Buy
46,430
+3,572
+8% +$52.8K ﹤0.01% 2657
2025
Q4 		$1.31M Sell
42,858
-4,259
-9% -$114K ﹤0.01% 2091
2025
Q3 		$936K Buy
47,117
+28,678
+156% +$504K ﹤0.01% 2285
2025
Q2 		$268K Buy
18,439
+5,559
+43% +$78.7K ﹤0.01% 3063
2025
Q1 		$158K Buy
+12,880
New +$240K ﹤0.01% 3222

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RhumbLine Advisers's BBNX Position: Q1 2026 in Review

RhumbLine Advisers increased its Beta Bionics (BBNX) stake by 8.3% in Q1 2026, buying an estimated $52.8K and bringing the position to 46,430 shares worth $465K. The position accounts for ﹤0.01% of the portfolio, ranked #2657.

RhumbLine Advisers first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.31M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • RhumbLine Advisers held 46,430 shares of Beta Bionics worth $465K as of Q1 2026.
  • RhumbLine Advisers bought 3,572 Beta Bionics shares in Q1 2026, an estimated $52.8K.
  • Beta Bionics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2657 holding.
  • RhumbLine Advisers first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • RhumbLine Advisers's Beta Bionics position peaked at $1.31M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.